Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited, often referred to simply as Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Established in 1951, the company has grown to become one of the largest privately-held pharmaceutical firms in the country, with a strong presence in over 100 countries across various regions, including North America, Europe, and Asia. Specialising in a diverse range of therapeutic areas, Cadila focuses on the development and manufacturing of generic and branded formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company is renowned for its commitment to quality and innovation, which has led to significant milestones, including the launch of several groundbreaking products. With a robust portfolio and a reputation for excellence, Cadila Pharmaceuticals continues to solidify its market position as a leader in the healthcare sector.
DitchCarbon Score
How does Cadila Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cadila Pharmaceuticals Limited's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cadila Pharmaceuticals Limited's reported carbon emissions
Cadila Pharmaceuticals Limited, headquartered in India, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments under initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. As of now, Cadila Pharmaceuticals has not cascaded any emissions data from a parent or related organization, indicating that their climate commitments and emissions reporting are independent. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are setting ambitious targets to reduce their carbon footprints. Cadila Pharmaceuticals may benefit from aligning with industry standards and best practices to enhance its climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cadila Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
